Skip to main content

Table 3 IC50 values in (µM) and (%) change for Sorafenib in combination with different doses of Thymoquinone (TQ) and/or Piperine (PIP) against HepG2 and MDA-MB-231

From: Thymoquinone, piperine, and sorafenib combinations attenuate liver and breast cancers progression: epigenetic and molecular docking approaches

 

IC50 of SOR (% change)

HepG2

MDA-MB-231

Sorafenib alone

10.83 ± 0.54 (0)

23.69 ± 0.85 (0)

SOR + TQ IC10

10.21 ± 0.41 (5.7)

22.24 ± 0.98 (6.1)

SOR + TQ IC20

8.55*** ± 0.24 (21.05)

19.48* ± 0.57 (17.77)

SOR + TQ IC30

5.05*** ± 0.81 (53.3)

15.75*** ± 0.75 (33.51)

SOR + TQ IC40

4.54*** ± 0.32 (58.7)

12.63*** ± 0.35 (46.68)

SOR + TQ IC50

3.91*** ± 0.45 (63.89)

11.75*** ± 0.47 (50.4)

SOR + PIP IC10

10.52 ± 0.72 (2.86)

21.35 ± 0.79 (9.87)

SOR + PIP IC20

10.24 ± 0.47 (5.44)

19.20* ± 0.53 (18.95)

SOR + PIP IC30

7.57** ± 0.82 (30.1)

14.75*** ± 0.437 (37.73)

SOR + PIP IC40

5.12*** ± 0.22 (52.72)

10.85*** ± 0.48 (54.2)

SOR + PIP IC50

3.14*** ± 0.18 (71.0)

10.5*** ± 0.37 (55.67)

SOR + TQ IC10 + PIP IC10

9.34* ± 0.42 (13.7)

19.54* ± 0.82 (17.51)

SOR + TQ IC20 + PIP IC20

7.88*** ± 0.29 (27.23)

16.33*** ± 0.57 (31.06)

SOR + TQ IC30 + PIP IC30

4.24*** ± 0.32 (60.84)

12.47*** ± 0.90 (47.36)

SOR + TQ IC40 + PIP IC40

3.17*** ± 0.40 (70.72)

10.48*** ± 0.37 (55.76)

SOR + TQ IC50 + PIP IC50

1.54*** ± 0.12 (85.78)

5.89*** ± 0.65 (75.13)

  1. Data are represented as mean ± standard derivation of three independent experiments. Student paired t-test was used to determine significantly-different IC50 values (µM) compared to Sorafenib IC50; * p ˂ 0.05, ** p ˂ 0.01, and *** p ˂ 0.001